EXIT071
EXIT071 is an innovative startup company dedicated to advancing exosome research through proprietary microfluidic technology. They focus on analyzing novel exosome biomarkers with a platform that purifies, concentrates, and separates complex biological samples, aiming to unlock the potential of exosomes for non-invasive diagnostics and therapeutics.
Industries
Nr. of Employees
small (1-50)
Products
Exosome Isolation
A proprietary technology, dzITP, for efficient isolation and characterization of exosomes from various samples.
Biomarker Discovery
An integrated platform for exosome isolation and molecular analysis, enabling high-quality biomarker discovery.
Exosome Analysis Services
Services offered include exosome isolation, purity characterization, and biomarker analysis.
dzITP Technology
A patented technology for enrichment, separation, and filtering of analytes in a microfluidic chip.
Exosome Isolation
A proprietary technology, dzITP, for efficient isolation and characterization of exosomes from various samples.
Biomarker Discovery
An integrated platform for exosome isolation and molecular analysis, enabling high-quality biomarker discovery.
Exosome Analysis Services
Services offered include exosome isolation, purity characterization, and biomarker analysis.
dzITP Technology
A patented technology for enrichment, separation, and filtering of analytes in a microfluidic chip.
Services
Isolation of extracellular vesicles from biological fluids using microfluidic electrophoretic separation techniques.
Analytical characterization of exosome sample purity and quantification of impurities following isolation.
Molecular analysis of isolated exosomes using metabolomics, lipidomics, proteomics and transcriptomics to identify and validate biomarkers.
Isolation of extracellular vesicles from biological fluids using microfluidic electrophoretic separation techniques.
Analytical characterization of exosome sample purity and quantification of impurities following isolation.
Molecular analysis of isolated exosomes using metabolomics, lipidomics, proteomics and transcriptomics to identify and validate biomarkers.
Expertise Areas
- Exosome biomarker discovery
- Microfluidic device development
- Electrophoretic separation methods (isotachophoresis)
- Analytical chemistry and metabolomics/lipidomics
Key Technologies
- Depletion-zone isotachophoresis (isotachophoresis-based microfluidic separation)
- Microfluidic chips for nanoscale particle handling
- Electrophoretic mobility-based separation
- Exosome isolation workflows
News & Updates
EXIT071 recently participated in an academic startup competition.
Yuliya Shakalisava was interviewed by Leidsch Dagblad to learn more about exosomes.
EXIT071 was awarded €350,000 proof of concept investment from UNIIQ and LEH.
EXIT071 recently participated in an academic startup competition.
Yuliya Shakalisava was interviewed by Leidsch Dagblad to learn more about exosomes.
EXIT071 was awarded €350,000 proof of concept investment from UNIIQ and LEH.